Effects of urban PM2.5 on primary sinonasal epithelial cells in individuals with chronic rhinosinusitis

Fine particulate matter (PM2.5), airborne particles with an aerodynamic diameter of ≤2.5 µm, a major air pollutant, has been implicated in sinonasal inflammatory diseases such as chronic rhinosinusitis (CRS) even at levels below national air quality standards. PM2.5 is thought to exacerbate CRS by compromising the epithelial barrier, impairing mucociliary clearance, and promoting inflammation. However, evidence linking PM2.5 exposure to sinonasal epithelial remodeling remains limited. This study investigated the effects of environmentally relevant doses of urban PM2.5 organic extract (PM2.5 OE) on primary sinonasal epithelial cell cultures derived from individuals with and without CRS. We hypothesized that PM2.5 OE exposure would induce transcriptional changes indicative of mucociliary remodeling, reduce transepithelial resistance, and increase inflammatory cytokine production. Primary nasal epithelial cells from healthy (N = 8) and CRS subjects (N = 10) were differentiated in an air-liquid interface, followed by acute (24-h) and subacute (5-day) exposure to an environmentally relevant dose of PM2.5 OE (9 μg/ml; 1.34 µg/cm2) or the vehicle control. PM2.5 OE exposure did not significantly alter these outcomes, regardless of disease status. Instead, variation was primarily driven by biological sex and CRS, with male CRS samples exhibiting downregulation of cilia assembly pathways. Cytokine production from unexposed cultures demonstrated sex-specific differences, with female-derived cultures displaying a more pro-inflammatory profile, highlighting intrinsic immune variability. These findings underscore the importance of biological sex and disease status when evaluating environmental exposures, suggesting that longer exposures may be necessary to fully capture PM2.5 OE-induced effects. This work highlights the need to investigate the crosstalk between environmental exposures and individual-specific factors influencing CRS disease progression.